Indication
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Medicine details
- Medicine name:
- deucravacitinib (Sotyktu)
- SMC ID:
- SMC2581
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Publication due date:
- 11 December 2023
- Patient group submission deadline:
- 02 October 2023